SOUTH SAN FRANCISCO, Calif.,
Sept. 19, 2017 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the Cantor Fitzgerald Global Healthcare
Conference in New York City on
Tuesday, September 26, 2017 at
2:15pm EDT.
To access the live webcast of the presentation or the subsequent
archived recording, log on to www.rigel.com. Please connect to
Rigel's website several minutes prior to the start of the live
webcast to ensure adequate time for any software download that may
be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematological disorders, cancer and rare diseases. Rigel's
pioneering research focuses on signaling pathways that are critical
to disease mechanisms. The company's current clinical programs
include clinical trials of fostamatinib, an oral spleen tyrosine
kinase (SYK) inhibitor, in a number of indications. Rigel has
submitted an NDA to the FDA for fostamatinib in patients with
chronic or persistent immune thrombocytopenia (ITP). In addition,
Rigel has product candidates in development with partners BerGenBio
AS, Daiichi Sankyo and Aclaris Therapeutics.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: jessica.daitch@inventivhealth.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-cantor-fitzgerald-global-healthcare-conference-300521736.html
SOURCE Rigel Pharmaceuticals, Inc.